LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation

Journal of Clinical Investigation

Volumn 107, Issue 12, 2001, Pages 1581-1589

  Cooke, K R ^a   Gerbitz, A ^a   Crawford, J M ^a   Teshima, T ^a   Hill, G R ^a   Tesolin, A ^a   Rossignol, D P ^a   Ferrara, J L M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LIPID A; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE;

EID: 0034978248     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI12156     Document Type: Article

References (57)

1. Principles of graft-vs.-leukemia reactivity
2. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
3. Graft versus host disease
4. Cytokine dysregulation in acute graft-versus-host disease
5. Endotoxin and disease mechanisms
6. Biochemistry of endotoxins
7. Cytokine cascades in acute graft-versus-host disease
8. IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease
9. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease
10. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation
11. Total body irradiation effects on acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines
12. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease
13. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin
14. Tumor necrosis factor-α production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft versus host disease
15. Experimental and clinical gnotobiotics: Influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation
16. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora
17. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment
18. Protection against graft versus host disease by gut sterilization?
19. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation
20. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: Final results and long term follow-up of an open-label prospective randomized trial
21. Graft-versus-leukemia reactions after bone marrow transplantation
22. Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: Importance of a graft-versus-leukemia effect
23. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation
24. Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction
25. Keratinocyte growth factor (KGF) separates graft versus leukemia effects from graft-versus-host disease
26. E5531, a pure endotoxin antagonist of high potency
27. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation
28. Diagnosis of graft-versus-host disease in mice transplanted across minor histocompatibility barriers
29. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease
30. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies
31. Graft-versus-host disease of the liver
32. The biology of graft-versus-host reactions
33. CD28 engraftment and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo
34. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells
35. T cell stimulation in vivo by lipopolysaccharide (LPS)
36. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation
37. Inflammatory reactions induced by pretransplant conditioning: An alternative target for modulation of acute GVHD and complications following allogeneic bone marrow transplantation
38. TNF-alpha levels are increased during bone marrow transplant conditioning in patients who develop acute GVHD
39. High response of TNFα secretion in vivo in patients undergoing BMT may be associated with the -308 bp TNF-alpha-gene enhancer-polymorphism
40. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF-alpha) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF-alpha (MAK 195F)
41. Progressive accumulation of bacterial lipopolysaccharide in vivo during murine acute graft-versus-host disease
42. The role of endotoxin in the pathogenesis of acute graft-versus-host disease
43. Differential roles of IL-1 and TNFα on graft-versus-host disease and graft versus leukemia
44. The gut mucosal barrier in bone marrow transplantation
45. Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation
46. Effect of IgM-enriched intravenous immunoglobulin (pentaglobin) on endotoxemia and anti-endotoxin antibodies in bone marrow transplantation
47. Role of bacterial microflora in development of intestinal lesions from graft versus host disease
48. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation
49. Antibody titers to a rough-mutant strain of Escherichia coli in patients undergoing allogeneic bone marrow transplantation
50. Anti-endotoxin antibody for prevention of acute GVHD
51. The graft-versus-leukemia effect
52. Graft versus leukemia
53. Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease
54. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation
55. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin
56. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia
57. Synthetic endotoxin antagonists